Sai Parenteral IPO: Subscription Slow, GMP at Zero in 2026

Introduction to Sai Parenteral's Public Offering

Sai Parenteral Limited, a pharmaceutical company specializing in Branded Generic Formulations and Contract Development and Manufacturing (CDMO), has launched its Initial Public Offering (IPO). The issue opened for subscription on March 24, 2026, and aims to raise ₹408.79 crores from the primary market. However, the initial response from investors has been cautious, with the IPO recording a slow subscription rate in its first two days. Compounding the lukewarm reception, the Grey Market Premium (GMP) for the issue stands at zero, suggesting expectations of a flat listing.

IPO Structure and Key Details

The public issue is a combination of a fresh issue of 0.73 crore shares, aggregating to ₹285 crores, and an Offer for Sale (OFS) of 0.32 crore shares, amounting to ₹123.79 crores. The company has set the price band for the IPO at ₹372 to ₹392 per equity share, with a face value of ₹5 per share. The funds raised from the fresh issue are intended to be used for funding the company's working capital requirements and for general corporate purposes. The shares are proposed to be listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE), with a tentative listing date of April 2, 2026.

Subscription Status So Far

The IPO experienced a slow start on its first day, March 24, achieving only a 4% overall subscription. Bids were received for just 3.35 lakh shares against the 75.22 lakh shares on offer. The retail segment showed minimal interest, subscribing to only 3% of its allocated quota. By the end of the second day, the overall subscription improved to 0.42 times, or 42%. The Non-Institutional Investors (NIIs) category was subscribed 1.05 times, while the Qualified Institutional Buyers (QIBs) portion was subscribed 0.60 times. However, retail investor participation remained notably low at just 5% of the allotted portion.

Grey Market Premium and Listing Expectations

As of March 26, 2026, the Grey Market Premium (GMP) for Sai Parenteral's IPO is ₹0. The GMP is an unofficial indicator of how an IPO might perform on its listing day. A zero GMP suggests that the shares are trading at their issue price in the grey market, signaling the possibility of a flat or muted debut on the stock exchanges. This lack of premium often reflects cautious sentiment among investors regarding the issue's valuation or broader market conditions. While the GMP is not a definitive predictor, it is closely watched by market participants to gauge short-term listing gains.

Company Profile and Financials

Sai Parenteral Limited operates in the pharmaceutical sector with a business model that includes both Branded Generic Formulations and CDMO services. Its product portfolio is diverse, covering various therapeutic areas and dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. This diversified offering caters to both high-value and high-volume market segments. Before the IPO opened to the public, the company successfully raised ₹122.63 crores from five anchor investors on March 23, 2026, indicating some level of institutional confidence.

How to Apply for the IPO

Investors interested in applying for the Sai Parenteral IPO can do so through various channels until the closing date of March 27, 2026. Applications can be submitted online using either UPI or ASBA (Application Supported by Blocked Amount) as a payment method. Most brokerage firms, including Zerodha, Upstox, and 5Paisa, offer UPI-based IPO applications through their platforms. Alternatively, investors can use the ASBA facility available through the net banking portals of their respective banks. The allotment of shares is expected to be finalized on March 30, 2026, with shares being credited to the demat accounts of successful applicants by April 1, 2026.

Conclusion and Outlook

The Sai Parenteral IPO has met with a subdued response in its initial days, marked by low subscription figures, particularly from retail investors, and a non-existent grey market premium. While the anchor investor portion was fully subscribed, the broader market sentiment appears cautious. Investors will be closely watching the subscription numbers on the final day of bidding. The final outcome and listing performance on April 2 will depend on whether demand picks up and how the broader market performs in the interim.